On January 9, Glonghui reported that Johnson & Johnson announced on Wednesday that its proposed drug posdinemab for the treatment of Alzheimer's disease has been granted Fast Track designation by the USA Food and Drug Administration (FDA). Johnson & Johnson is conducting a Phase 2b study on early Alzheimer's patients to investigate an internally developed tau-targeted monoclonal antibody. The company stated that posdinemab shows potential against disease-related phosphorylated tau proteins in the cerebrospinal fluid of Alzheimer's patients, and it has been shown to prevent the development and Diffusion of tau protein aggregation in nonclinical models of memory deprivation disease.